{"nctId":"NCT02235909","briefTitle":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","startDateStruct":{"date":"2015-03-30","type":"ACTUAL"},"conditions":["Hypertension"],"count":377,"armGroups":[{"label":"Double-blind: Azilsartan Medoxomil - Low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Azilsartan Medoxomil Low-dose"]},{"label":"Double blind phase: Losartan","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Losartan"]},{"label":"Withdrawal Phase: Azilsartan medoxomil low-dose (AZM-L)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Azilsartan Medoxomil Low-dose"]},{"label":"Withdrawal Phase: Placebo to match azilsartan medoxomil low dose (AZM-L)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Losartan"]},{"label":"Open Label Phase: Azilsartan Medoxomil","type":"EXPERIMENTAL","interventionNames":["Drug: Azilsartan Medoxomil Low-dose"]},{"label":"Withdrawal Phase: Losartan 50 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Losartan"]},{"label":"Withdrawal Phase: Placebo to Losartan","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for Losartan"]},{"label":"Double-blind: Azilsartan Medoxomil - Medium dose","type":"EXPERIMENTAL","interventionNames":["Drug: Azilsartan Medoxomil Low-dose","Drug: Placebo for Losartan","Drug: Azilsartan Medoxomil Medium-dose (20 mg)"]},{"label":"Double-blind: Azilsartan Medoxomil - High dose (AZM-H)","type":"EXPERIMENTAL","interventionNames":["Drug: Azilsartan Medoxomil High-dose (40 mg)"]},{"label":"Withdrawal: Azilsartan Medoxomil - Medium dose","type":"EXPERIMENTAL","interventionNames":["Drug: Azilsartan Medoxomil Low-dose","Drug: Azilsartan Medoxomil Medium-dose (20 mg)"]},{"label":"Withdrawal: Azilsartan Medoxomil - High dose","type":"EXPERIMENTAL","interventionNames":["Drug: Azilsartan Medoxomil High-dose (40 mg)"]},{"label":"Withdrawal Phase: Placebo to match azilsartan medoxomil medium dose (AZM-M)","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo for Azilsartan Medoxomil"]},{"label":"Withdrawal Phase: Placebo to match azilsartan medoxomil high dose (AZM-H)","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo for Azilsartan Medoxomil"]}],"interventions":[{"name":"Azilsartan Medoxomil Low-dose","otherNames":["AR14","AZM-L"]},{"name":"Losartan","otherNames":["Cozaar"]},{"name":"Placebo for Azilsartan Medoxomil","otherNames":[]},{"name":"Placebo for Losartan","otherNames":[]},{"name":"Azilsartan Medoxomil Medium-dose (20 mg)","otherNames":["AR14","AZM-M"]},{"name":"Azilsartan Medoxomil High-dose (40 mg)","otherNames":["AR14","AZM-H"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject has hypertension (primary or secondary) defined as clinic Seated Diastolic BP ≥95th percentile (by age, gender, and height) or ≥90th percentile (by age, gender, height) if chronic renal disease, diabetes, heart failure or hypertensive target organ damage is present\n\n  1. If currently treated: The subject has a documented historical diagnosis of hypertension AND a post-washout clinic Seated Diastolic BP meeting the above criteria on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)\n  2. If currently untreated: The subject has elevated Seated Diastolic BP meeting the above criteria on 3 separate occasions before Randomization, including on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)\n* The subject is male or female and aged 6 to \\<18 years at Baseline and weighs at least 25 kg\n* The subject agrees to continue their previously implemented nonpharmacological life style modifications if begun prior to Screening. Note: For subjects participating in a weight loss program, the weight maintenance\n\nExclusion Criteria:\n\n* The subject has a clinic Seated Diastolic BP greater than 15 mm Hg and/or Seated Diastolic BP greater than 10 mm Hg above the 99th percentile for age, gender, and height as confirmed by the average (arithmetic mean) of 3 serial clinic seated BP measurements at Screening/Visit 1\n* The subject has a diagnosis of malignant or accelerated hypertension\n* The subject is currently treated with more than 2 antihypertensive agents\n* The subject or parent/legal guardian is not willing for the subject's previous antihypertensive medications to be stopped\n* The subject has participated in the intensive, active weight-loss phase of a weight-loss program within 30 days prior to Screening/Visit 1\n* The subject has any of the following: severe renal impairment (eGFR \\<30 mL/min/1.73 m2 by the Schwartz formula); is currently undergoing dialysis treatment; renovascular disease affecting both kidneys or a solitary kidney; severe nephrotic syndrome not in remission; or serum albumin \\<2.5 g/dL\n* The subject has a history or clinical manifestations of severe cardiovascular, hepato-biliary, gastrointestinal, endocrine-metabolic (e.g., hyperthyroidism, Cushing's syndrome), hematologic, immunologic, genito-urinary, or psychiatric disease, cancer, and/or any conditions that would interfere with the health status of the subject through study participation, or would jeopardize study integrity in the opinion of the investigator\n* The subject is suffering from uncorrected coarctation of the aorta, or hemodynamically significant left ventricular outflow tract obstruction due to eg, aortic valvular disease, or is likely to undergo a procedure known to affect blood pressure (eg, repair of arterial anomalies) during the course of the study\n* The subject is poorly controlled diabetic defined as having a glycosylated hemoglobin value \\>8.5% at Screening/Visit 1\n* The subject has hyperkalemia as defined by the central laboratory's normal reference range or any pertinent electrolyte disorders at Screening/Visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Seated Diastolic Blood Pressure Between AZM and Placebo","description":"Change in Seated Diastolic Blood Pressure from Week 6/Final visit of DB Phase to Week 8/Final Visit of the Withdrawal Phase, analysis of study subjects randomized to receiving placebo at Week 6 of treatment versus those who remained on treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"8"},{"groupId":"OG001","value":"-1.6","spread":"6.69"}]}]}]},{"type":"SECONDARY","title":"Change in Trough Seated Systolic Blood Pressure","description":"Change in Trough Seated Systolic Blood Pressure from Week 6 of the Double-Blind Phase to Week 8 of the Withdrawal Phase Between AZM and Placebo, analysis of study subjects randomized to receiving placebo at Week 6 of treatment versus those who remained on treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"9.96"},{"groupId":"OG001","value":"-2.3","spread":"8.72"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Arterial Pressure","description":"Change in Mean Arterial Pressure from Week 6 of the Double-Blind Phase to Week 8 of the Withdrawal Phase Between AZM and Placebo, analysis of study subjects randomized to receiving placebo at Week 6 of treatment versus those who remained on treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"7.43"},{"groupId":"OG001","value":"-1.8","spread":"6.63"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":289},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Gastroenteritis"]}}}